Is the Yellow Card Road Going in the Right Direction? Stephen J. W. Evans Editorial 07 May 2015 Pages: 517 - 518
PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials Kristopher J. SwigerSeth S. Martin Current Opinion 20 May 2015 Pages: 519 - 526
Oral Anticoagulants and Risk of Nephropathy Vinay Narasimha KrishnaDavid G. WarnockDana V. Rizk Leading Article 26 April 2015 Pages: 527 - 533
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection Anna GirardiEmanuel RaschiFabrizio De Ponti Review Article Open access 12 April 2015 Pages: 535 - 551
Harmonizing Post-Market Surveillance of Prescription Drug Misuse: A Systematic Review of Observational Studies Using Routinely Collected Data (2000–2013) Bianca BlanchNicholas A. BuckleySallie-Anne Pearson Systematic Review 13 May 2015 Pages: 553 - 564
Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications Aaron S. KesselheimEric G. CampbellJerry Avorn Study Design 13 May 2015 Pages: 565 - 575
Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases Gianmario CandoreKristina JuhlinJim Slattery Original Research Article 22 April 2015 Pages: 577 - 587
Incorporating Linked Healthcare Claims to Improve Confounding Control in a Study of In-Hospital Medication Use Jessica M. FranklinWesley EddingsJeremy A. Rassen Original Research Article 03 May 2015 Pages: 589 - 600